Dr. Sebastian Grosicki, Medical University of Silesia, presents the results of the MagnetisMM-5 study a phase 3, multicenter, randomized, open-label trial designed to assess the efficacy and safety of elranatamab monotherapy or in combination with daratumumab in relapsed refractory multiple myeloma patients.
Background:
In the MagnetisMM-3 study (NCT04649359), the humanized bispecific antibody Elranatamab (PF-06863135) was tested as a monotherapy in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM). Elranatamab targets both B cell maturation antigen (BCMA)-expressing MM cells and CD3-expressing T cells, leading to T cell-mediated cytotoxicity. The results showed that elranatamab was well tolerated and produced an overall response rate of 60.6% at the recommended phase 2 dose.
The MagnetisMM-5 study (NCT05020236) is a phase 3, multicenter, randomized, open-label trial designed to assess the efficacy and safety of elranatamab monotherapy or in combination with daratumumab in RRMM patients. In this study, we present the results from the safety lead-in cohort (Part 1).
Conclusions:
SC elranatamab + SC daratumumab demonstrated promising early responses with a manageable safety profile in pts with RRMM, consistent with the SC elranatamab monotherapy results from MagnetisMM-3. No DLTs were observed, and no pts experienced ICANS or greatern than or equal G3 CRS with the 2 step-up priming regimen for elranatamab. These results support continued development of elranatamab in combination with daratumumab for pts with RRMM. In Part 2 of MagnetisMM-5, pts will be randomized 1:1:1 to receive SC elranatamab monotherapy, or SC elranatamab + SC daratumumab, or SC daratumumab + oral pomalidomide + oral dexamethasone.
Authors:
Sebastian Grosicki, MD, PhD, Ulf-Henrik Mellqvist, Łukasz Pruchniewski, MD, PhD, Jacob Crafoord, MD, Suzanne Trudel, Chang-Ki Min, MD, PhD, Darrell White, MD, Adrian Alegre, MD, PhD, Markus Hansson, MD, PhD, Takashi Ikeda, MD, PhD, Kazutaka Sunami, Eric Leip, PhD, Arthur Kudla, PhD, Gregory Finn, PhD and Youngil Koh, MD, PhD
ASH Abstract #1921: https://ash.confex.com/ash/2022/webprogram/Paper162738.html
